Bormioli Pharma completes acquisition of GCL Pharma

16.04.2020

Parma (Italy) 16 April 2020 - Bormioli Pharma, a Triton Fund IV company, has successfully completed the acquisition of 100% of GCL Pharma, an Italian company based in Vasto (Chieti) previously part of Guala Closures Group and specialized in the production of rubber stoppers and aluminium closures for pharmaceutical applications.

This acquisition represents a further significant step on the growth path that Bormioli Pharma has started with the acquisition of the German company Remy & Geiser last autumn, and the recent investments in the industrial sites of Bergantino (Rovigo) and San Vito al Tagliamento (Pordenone). The company is expanding its technological platform adding new solutions to the product range offered to the market, also strengthening its role as a leading partner for the global pharmaceutical industry.

GCL Pharma will be completely integrated within the Bormioli Pharma group and will change its business name in Bormioli Pharma Vasto Srl.

 

About Bormioli

Bormioli Pharma operates in close partnership with the pharmaceutical industry and with all the businesses that are engineering the future of healthcare. As a world-renowned player in the packaging industry, Bormioli Pharma serves the pharmaceutical and biopharmaceutical market with integrated glass and plastic containers, closures, and packaging accessories using state-of-the-art materials and technologies. 

Each product is a unique combination of rigorous studies, cutting-edge technology, extreme testing, advanced industrial processes, and the finest materials. 

As a partner to the pharmaceutical industry, Bormioli Pharma invests and innovates with one goal in mind: improving people’s lives. Bormioli Pharma employees over 1200 people, produces 6.5 billion pieces every year and had an annual turnover of approximately €250 million in 2019.

For further information: www.bormiolipharma.com/en/#

About Triton

Since its establishment in 1997, Triton has sponsored nine funds, focusing on businesses in the industrial, business services, consumer and healthcare sectors.

The Triton funds invest in and support the positive development of medium-sized businesses headquartered in Europe. Triton seeks to contribute to the building of better businesses for the longer term.

Triton and its executives wish to be agents of positive change towards sustainable operational improvements and growth.

The 42 companies currently in Triton's portfolio have combined sales of around €17.2 billion and around 81,400 employees.

For further information: www.triton-partners.com

Press Contacts

Triton
Anja Schlenstedt
Bormioli Pharma
Daniele Rurale
Bormioli Pharma
Ivan Martelli